535 results on '"Verges B"'
Search Results
2. Thyroïdites : où en est-on en 2019 ?
3. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
4. L’hyperglycémie chronique n’est pas impliquée dans la perte de fonction de l’apolipoprotéine C1 chez les patients diabétiques de type 1
5. Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2
6. Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings
7. Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction
8. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry
9. CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes
10. Effects of anti-somatostatin agents on glucose metabolism
11. Prise en charge des dyslipidémies : quelles nouvelles recommandations?
12. IDF23-0544 Frequency of silent coronary artery disease in type 2 diabetics : preliminary results of a cross sectional study
13. Consensus statement on the management of dyslipidaemias in adults
14. Consensus statement on the management of dyslipidaemias in adults
15. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients
16. Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes
17. Neuropathie induite par la thérapie chez les patients diabétiques : ne pas traiter trop vite !
18. Hyperglycémie induite par l’analogue de somatostatine pasiréotide au cours de la maladie de Cushing
19. Diabète secondaire aux inhibiteurs mTOR
20. Potential risks associated with increased plasma plant-sterol levels
21. Découverte d’une nouvelle mutation c.631C>T p.Gln211 de l’exon 4 du gène KDM1A avec syndrome de cushing et hyperplasie macronodulaire des surrénales : à propos d’un cas sous corticoide inhalé
22. Adverse effects and safety of SGLT-2 inhibitors
23. Une nouvelle indication du fénofibrate ? La rétinopathie diabétique, en Australie
24. Phytostérols, phytostanols, et risque cardiovasculaire
25. Lipides et diabète de type 1
26. Glycation des HDL et conséquences chez le patient diabétique
27. Effets cardiovasculaires des inhibiteurs de la DPP-4
28. Physical activity and type 2 diabetes. Recommandations of the SFD (Francophone Diabetes Society) diabetes and physical activity working group
29. Un nouveau système d’injection d’insuline « Daily Dose » : pour quel usage ?
30. Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide
31. Évaluation du niveau de littératie en santé chez les patients en essai clinique
32. Adrenal lymphoma: presentation, management and prognosis
33. Quelle place pour le traitement par pompe à insuline externe dans le diabète de type 2 ?
34. Effects of a home-based rehabilitation program in obese type 2 diabetics
35. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes
36. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
37. Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes
38. Type 2 diabetes treatment intensification in general practice in France in 2008–2009: the DIAttitude Study
39. Quelle place pour les fibrates après l’étude ACCORD- Lipids ?
40. Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
41. Outcome in AN adult patients: A 13-year follow-up in 484 patients
42. GLP-1 receptor agonists in NAFLD
43. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
44. Adénome hypophysaire et NEM1–nouvelles données issues de la cohorte du GTE (Groupe d’étude des tumeurs endocrines)
45. High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study
46. Complications cardiovasculaires du diabète de type 1: Cardiovascular complications in type 1 diabetes
47. Risque cardiovasculaire résiduel du patient diabétique de type 2: Cardiovascular residual risk in patients with type 2 diabetes
48. Évaluation du risque cardiovasculaire chez le diabétique de type 2 et prescription d’une activité physique
49. L’intérêt démontré des statines chez les patients diabétiques de type 2: Evidence for statin use in patients with type 2 diabetes
50. Cardiovascular complications in type 1 diabetes mellitus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.